WARNING: “Buffett Indicator” flashing for first time in 50 years

Warren Buffett has sold a staggering $97 billion worth of stocks this year... But why? Our research indicates the Oracle of Omaha is quietly preparing for a historic market crash. His most reliable crash indicator - the "Buffett indicator" - just flashed red for the first time in 25 years.

Take these 4 steps today to protect your retirement NOW

Ashish Mandelia Biography and Net Worth

VP of Mersana Therapeutics

Ashish Mandelia is the VP, Controller & Principal Accounting Officer at Mersana Therapeutics Inc.

What is Ashish Mandelia's net worth?: The estimated net worth of Ashish Mandelia is at least $81,788.80 as of October 2nd, 2024. Mr. Mandelia owns 51,118 shares of Mersana Therapeutics stock worth more than $81,789 as of December 21st. This net worth evaluation does not reflect any other assets that Mr. Mandelia may own. Learn More about Ashish Mandelia's net worth.
How old is Ashish Mandelia?: Mr. Mandelia is currently 49 years old. There are 5 older executives and no younger executives at Mersana Therapeutics. The oldest executive at Mersana Therapeutics is Dr. Martin H. Huber M.D., President, CEO & Director, who is 63 years old. Learn More on Ashish Mandelia's age.
How do I contact Ashish Mandelia?: The corporate mailing address for Mr. Mandelia and other Mersana Therapeutics executives is 840 MEMORIAL DRIVE, CAMBRIDGE MA, 02139. Mersana Therapeutics can also be reached via phone at (617) 498-0020 and via email at [email protected]. Learn More on Ashish Mandelia's contact information.
Has Ashish Mandelia been buying or selling shares of Mersana Therapeutics?: During the past quarter, Ashish Mandelia has sold $9,710.00 in Mersana Therapeutics stock. Most recently, Ashish Mandelia sold 4,855 shares of the business's stock in a transaction on Wednesday, October 2nd. The shares were sold at an average price of $2.00, for a transaction totalling $9,710.00. Following the completion of the sale, the chief accounting officer now directly owns 51,118 shares of the company's stock, valued at $102,236. Learn More on Ashish Mandelia's trading history.
Who are Mersana Therapeutics' active insiders?: Mersana Therapeutics' insider roster includes Lawrence Alleva (Director), Andrew Hack (Director), Timothy Lowinger (Insider), Ashish Mandelia (VP), Anna Protopapas (CEO), and Arvin Yang (Insider). Learn More on Mersana Therapeutics' active insiders.
Are insiders buying or selling shares of Mersana Therapeutics?: During the last twelve months, insiders at the sold shares 9 times. They sold a total of 117,957 shares worth more than $256,846.84. The most recent insider tranaction occured on October, 28th when SVP Mohan Bala sold 1,884 shares worth more than $3,579.60. Insiders at Mersana Therapeutics own 11.8% of the company. Learn More about insider trades at Mersana Therapeutics.
Information on this page was last updated on 10/28/2024.

Ashish Mandelia Insider Trading History at Mersana Therapeutics

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
10/2/2024	Sell	4,855	$2.00	$9,710.00	51,118
1/16/2024	Sell	5,025	$2.71	$13,617.75	23,328
1/17/2023	Sell	3,575	$5.74	$20,520.50	13,619
1/18/2022	Sell	1,982	$5.92	$11,733.44
1/19/2021	Sell	545	$21.28	$11,597.60	834
1/4/2021	Sell	247	$26.76	$6,609.72
7/2/2020	Sell	3,383	$22.49	$76,083.67

Ashish Mandelia Buying and Selling Activity at Mersana Therapeutics

Mersana Therapeutics Company Overview

Mersana Therapeutics, Inc., a clinical stage biopharmaceutical company, develops antibody drug conjugates (ADC) for cancer patients with unmet needs. The company develops XMT-1660, a B7-H4-targeted Dolasynthen ADC candidate; and XMT-2056, an immunosynthen ADC. It has research and development collaborations with Janssen Biotech, Inc., Ares Trading S.A., Merck KGaA, and Asana BioSciences, LLC for the development of ADC product candidates. The company was formerly known as Nanopharma Corp. and changed its name to Mersana Therapeutics, Inc. in November 2005. Mersana Therapeutics, Inc. was incorporated in 2001 and is headquartered in Cambridge, Massachusetts.

Today's Range

Now: $1.60

$1.56

$1.68

50 Day Range

MA: $2.16

$1.60

$2.68

2 Week Range

Now: $1.60

$1.22

$6.28

Volume

2,724,133 shs

Average Volume

1,583,316 shs

Market Capitalization

$197.65 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.4

Did You See Trump’s Bombshell Exec. Order 001?

From Banyan Hill Publishing | Ad

Biden broke it... Now Trump is going to fix it. Starting with "Exec. Order 001."

I put all the details together for you here — but please hurry.

Ashish Mandelia Biography and Net Worth

What is Ashish Mandelia's net worth?

How old is Ashish Mandelia?

How do I contact Ashish Mandelia?

Has Ashish Mandelia been buying or selling shares of Mersana Therapeutics?

Who are Mersana Therapeutics' active insiders?

Are insiders buying or selling shares of Mersana Therapeutics?